Suchergebnisse - "Frerichs, Kristine A"

PubPharm (19)

1

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma : importance of immunoglobulin supplementation

enthalten in: Blood advances | 2024

von Frerichs, K. | Verkleij, C. | Mateos, M. | +21

2

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity

enthalten in: EBioMedicine | 2023

von Hiemstra, I. | Santegoets, K. | Janmaat, M. | +17

3

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma

enthalten in: HemaSphere | 2023

von Verkleij, C. | Frerichs, K. | Broekmans, M. | +24

4

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

enthalten in: Blood advances | 2021

von Frerichs, K. | Minnema, M. | Levin, M. | +11

5

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence

enthalten in: Science translational medicine | 2021

von Katsarou, A. | Sjöstrand, M. | Naik, J. | +21

6

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma

enthalten in: Journal of clinical medicine | 2021

von Hosny, M. | Verkleij, C. | van der Schans, J. | +4

7

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients

enthalten in: Cancers | 2021

von Frerichs, K. | Verkleij, C. | Dimopoulos, M. | +6

8

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

enthalten in: Blood advances | 2021

von Verkleij, C. | Broekmans, M. | van Duin, M. | +15

9

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

enthalten in: Cancers | 2020

von Verkleij, C. | Jhatakia, A. | Broekmans, M. | +5

10

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma

enthalten in: Oncotarget | 2020

von Verkleij, C. | Frerichs, K. | Broekmans, M. | +7